Mar 21, 2017 13:03 pm UTC| Business
A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn’s disease (the MAP US study) is ongoing in the U.S. and additional countriesThe open-label extension...
Mar 21, 2017 13:03 pm UTC| Business
A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn’s disease (the MAP US study) is ongoing in the U.S. and additional countriesThe open-label extension...
Mar 21, 2017 13:03 pm UTC| Business
A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn’s disease (the MAP US study) is ongoing in the U.S. and additional countriesThe open-label extension...
Mar 21, 2017 13:02 pm UTC| Business
SUNNYVALE, Calif., March 21, 2017 -- Finisar (NASDAQ:FNSR) today announced multiple optics product and technology demonstrations to be held this week during the OFC exhibition. The company will feature new module types,...
Mar 21, 2017 13:02 pm UTC| Business
SUNNYVALE, Calif., March 21, 2017 -- Finisar (NASDAQ:FNSR) today announced multiple optics product and technology demonstrations to be held this week during the OFC exhibition. The company will feature new module types,...
Mar 21, 2017 13:02 pm UTC| Business
SUNNYVALE, Calif., March 21, 2017 -- Finisar (NASDAQ:FNSR) today announced multiple optics product and technology demonstrations to be held this week during the OFC exhibition. The company will feature new module types,...
Enphase Energy Revolutionizes Residential Rooftop Solar Installations
Mar 21, 2017 13:02 pm UTC| Business
Enphase IQ Microinverter System Now Shipping in the U.S. PETALUMA, Calif., March 21, 2017 -- Enphase Energy, Inc. (NASDAQ:ENPH), a global energy technology company and the world’s leading supplier of solar...